Amneal Pharmaceuticals, Inc. (AMRX) – What Are Investment Firms Saying About This Stock?

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $21.25.

Several research analysts have commented on the stock. The Goldman Sachs Group restated a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. UBS Group reaffirmed a “buy” rating on shares of Amneal Pharmaceuticals in a report on Thursday, October 1st. Weiss Ratings upgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. JPMorgan Chase & Co. increased their price target on Amneal Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, October 22nd. Finally, Leerink Partners began coverage on Amneal Pharmaceuticals in a research note on Wednesday, September 9th. They issued an “outperform” rating and a $23.00 price objective on the stock.

Amneal Pharmaceuticals Price Performance

AMRX stock opened at $21.44 on Wednesday. Amneal Pharmaceuticals has a one year low of $9.99 and a one year high of $21.46. The company’s fifty day moving average price is $18.93 and its 200-day moving average price is $15.62.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The company had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. As a group, analysts anticipate that Amneal Pharmaceuticals will post 0.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, EVP Jason Daly sold 210,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. This represents a 85.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the transaction, the executive vice president directly owned 253,390 shares in the company, valued at $4,436,858.90. The trade was a 36.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 413,016 shares of company stock worth $7,216,567 over the last 90 days. 17.30% of the stock is owned by insiders.

Institutional Trading of Amneal Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its position in Amneal Pharmaceuticals by 72.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,549,572 shares of the company’s stock valued at $32,405,000 after purchasing an additional 1,069,400 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of Amneal Pharmaceuticals in the 2nd quarter worth approximately $17,573,000. Principal Financial Group Inc. lifted its position in shares of Amneal Pharmaceuticals by 527.9% in the 1st quarter. Principal Financial Group Inc. now owns 972,529 shares of the company’s stock worth $12,089,000 after purchasing an additional 817,652 shares during the period. Congress Asset Management Co. boosted its stake in shares of Amneal Pharmaceuticals by 94.7% during the third quarter. Congress Asset Management Co. now owns 1,524,355 shares of the company’s stock valued at $30,701,000 after purchasing an additional 741,577 shares in the last quarter. Finally, Quartz Partners LLC bought a new position in shares of Amneal Pharmaceuticals during the first quarter valued at approximately $5,559,000. 31.82% of the stock is currently owned by institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.